Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

363 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Global Insights from Patients, Providers, and Staff on Challenges and Solutions in Managing Neovascular Age-Related Macular Degeneration.
Loewenstein A, Sylvanowicz M, Amoaku WM, Aslam T, Cheung CMG, Eldem B, Finger RP, Gale RP, Kodjikian L, Koh A, Korobelnik JF, Lin X, Mitchell P, Murphy M, Okada M, Pearce I, Rodriguez FJ, Stern J, Talks SJ, Wong DT, Wong TY, Ziemssen F, Barratt J. Loewenstein A, et al. Among authors: korobelnik jf. Ophthalmol Ther. 2024 Dec 14. doi: 10.1007/s40123-024-01061-3. Online ahead of print. Ophthalmol Ther. 2024. PMID: 39673040
Improving Clinical Management of Diabetic Macular Edema: Insights from a Global Survey of Patients, Healthcare Providers, and Clinic Staff.
Ziemssen F, Sylvanowicz M, Amoaku WM, Aslam T, Eldem B, Finger RP, Gale RP, Kodjikian L, Korobelnik JF, Lin X, Loewenstein A, Mitchell P, Murphy M, Owens DR, Parker N, Pearce I, Rodríguez FJ, Stern J, Talks SJ, Wong DT, Wong TY, Barratt J. Ziemssen F, et al. Among authors: korobelnik jf. Ophthalmol Ther. 2024 Dec 14. doi: 10.1007/s40123-024-01060-4. Online ahead of print. Ophthalmol Ther. 2024. PMID: 39673039
Treatment regimens for optimising outcomes in patients with neovascular age-related macular degeneration.
Teo KYC, Eldem B, Joussen A, Koh A, Korobelnik JF, Li X, Loewenstein A, Lövestam-Adrian M, Navarro R, Okada AA, Pearce I, Rodríguez F, Wong D, Wu L, Zur D, Zarranz-Ventura J, Mitchell P, Chaudhary V, Lanzetta P. Teo KYC, et al. Among authors: korobelnik jf. Eye (Lond). 2024 Oct 8. doi: 10.1038/s41433-024-03370-0. Online ahead of print. Eye (Lond). 2024. PMID: 39379523 Review.
Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials.
Wong TY, Haskova Z, Asik K, Baumal CR, Csaky KG, Eter N, Ives JA, Jaffe GJ, Korobelnik JF, Lin H, Murata T, Ruamviboonsuk P, Schlottmann PG, Seres AI, Silverman D, Sun X, Tang Y, Wells JA, Yoon YH, Wykoff CC; YOSEMITE and RHINE Investigators. Wong TY, et al. Among authors: korobelnik jf. Ophthalmology. 2024 Jun;131(6):708-723. doi: 10.1016/j.ophtha.2023.12.026. Epub 2023 Dec 28. Ophthalmology. 2024. PMID: 38158159 Free article. Clinical Trial.
Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results.
Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jiao J, Li XY, Whitcup SM; Ozurdex GENEVA Study Group; Li J. Haller JA, et al. Ophthalmology. 2011 Dec;118(12):2453-60. doi: 10.1016/j.ophtha.2011.05.014. Epub 2011 Jul 20. Ophthalmology. 2011. PMID: 21764136 Clinical Trial.
Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials.
Heier JS, Lad EM, Holz FG, Rosenfeld PJ, Guymer RH, Boyer D, Grossi F, Baumal CR, Korobelnik JF, Slakter JS, Waheed NK, Metlapally R, Pearce I, Steinle N, Francone AA, Hu A, Lally DR, Deschatelets P, Francois C, Bliss C, Staurenghi G, Monés J, Singh RP, Ribeiro R, Wykoff CC; OAKS and DERBY study investigators. Heier JS, et al. Among authors: korobelnik jf. Lancet. 2023 Oct 21;402(10411):1434-1448. doi: 10.1016/S0140-6736(23)01520-9. Lancet. 2023. PMID: 37865470 Clinical Trial.
Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion.
Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jacques ML, Jiao J, Li XY, Whitcup SM; OZURDEX GENEVA Study Group. Haller JA, et al. Ophthalmology. 2010 Jun;117(6):1134-1146.e3. doi: 10.1016/j.ophtha.2010.03.032. Epub 2010 Apr 24. Ophthalmology. 2010. PMID: 20417567 Clinical Trial.
Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial.
Lanzetta P, Korobelnik JF, Heier JS, Leal S, Holz FG, Clark WL, Eichenbaum D, Iida T, Xiaodong S, Berliner AJ, Schulze A, Schmelter T, Schmidt-Ott U, Zhang X, Vitti R, Chu KW, Reed K, Rao R, Bhore R, Cheng Y, Sun W, Hirshberg B, Yancopoulos GD, Wong TY; PULSAR Investigators. Lanzetta P, et al. Among authors: korobelnik jf. Lancet. 2024 Mar 23;403(10432):1141-1152. doi: 10.1016/S0140-6736(24)00063-1. Epub 2024 Mar 7. Lancet. 2024. PMID: 38461841 Clinical Trial.
363 results